Pharmaceutical Waste Detection

Pharmaceutical waste is the most insidious type of anomaly because each individual transaction looks perfectly reasonable. An early refill by a few days, a re-authorization for the same molecule, a duplicate dispensation on the same day — each of these transactions passes all standard validations without triggering alerts.

But when these patterns are analyzed at scale — thousands of patients, hundreds of pharmacies, millions of transactions — the cumulative impact is enormous. Waste and utilization issues represent 20.3% of anomalous pharmaceutical spend, the largest category by volume in our analysis of Latin American health insurance claims.

Traditional authorization systems are not designed to detect waste. They are designed to verify that each individual transaction complies with coverage, formulary, and authorization rules. An early refill is a valid transaction — the patient has coverage, the medication is on the formulary, and the prescriber is legitimate. Only when compared with the previous dispensation of the same medication does the pattern become visible.

This problem is particularly relevant for health insurers in Latin America, where the lack of interoperability between pharmacies, prescribers, and insurers creates windows of opportunity for waste patterns that would persist indefinitely without proactive detection.

Same-molecule re-authorization occurs when a patient receives multiple authorizations for the same active ingredient, frequently in different presentations, brands, or concentrations. The result is that the patient has access to medication quantities exceeding what is clinically necessary.

This was the most common waste pattern on the book we analyzed: it affected 1 in 5 subscribers. Although the median cost per dispensation is relatively low ($13), the extremely high frequency made it a significant problem. On the ~50,000-subscriber book we observed $244,000 in one year.

Same-molecule re-authorizations frequently arise from fragmentation in the healthcare system. A patient sees multiple specialists who prescribe the same medication without knowing another already prescribed it. Or a patient changes pharmacies and the new pharmacy has no visibility into previous dispensations.

Inspector AI detects these patterns by comparing all of a patient's dispensations over time, identifying when the same active ingredient appears across multiple authorizations. This allows the insurer to intervene before the pattern consolidates, saving costs and improving patient safety by preventing the accumulation of excessive medication quantities.

The combined financial impact of waste patterns was substantial on the book we analyzed. Early refills came to $176,000 observed in one year. Same-molecule re-authorizations added $244,000. Together, just these two patterns represented over $420,000 on the book in avoidable waste.

But the impact extends beyond direct cost. Pharmaceutical waste also has implications for patient safety. Patients who stockpile medications face greater risk of dosing errors, inadvertent interactions, and use of expired medications. Duplicate re-authorizations can lead to cumulative doses exceeding safe limits — a pattern we have identified in 433 subscribers.

For health insurers, reducing pharmaceutical waste has a multiplier effect: it reduces direct costs, improves quality of care indicators, and strengthens the relationship with regulators by demonstrating active pharmaceutical risk management.

Inspector AI provides the visibility needed to transform waste from a hidden cost into a quantifiable improvement opportunity. With a proof of concept that completes in 3 weeks without system integration, insurers can see exactly how much waste exists in their data before committing significant resources.